Ori Gutwerg Net Worth

The estimated Net Worth of Ori Gutwerg is at least $5.37 Million dollars as of 5 June 2024. Mr Gutwerg owns over 2,985 units of ANI Pharmaceuticals Inc stock worth over $4,194,971 and over the last 4 years he sold ANIP stock worth over $1,170,846.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Gutwerg ANIP stock SEC Form 4 insiders trading

Mr has made over 2 trades of the ANI Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,985 units of ANIP stock worth $199,995 on 5 June 2024.

The largest trade he's ever made was selling 15,561 units of ANI Pharmaceuticals Inc stock on 23 August 2023 worth over $970,851. On average, Mr trades about 1,427 units every 22 days since 2021. As of 5 June 2024 he still owns at least 77,227 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of Mr Gutwerg stock trades at the bottom of the page.

Mr. Ori Gutwerg biography

Ori Gutwerg is the Sr. VP of Generics at ANI Pharmaceuticals Inc.

How old is Mr Gutwerg?

Mr Gutwerg is 47, he's been the Sr. VP of Generics of ANI Pharmaceuticals Inc since . There are 13 older and 1 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.

What's Mr Gutwerg's mailing address?

Ori's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.

What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Complete history of Mr Gutwerg stock trades at ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Schrepfer,
  Senior Vice President - New Business Development and Specialty Sales
• Stephen Carey,
  Corporate Secretary, Vice President, Finance and Chief Financial Officer
• James Marken,
  Senior Vice President - Operations and Product Development
• James G. Marken,
  Sr. VP of Operations & Product Devel.
• Robert Brown,
  Independent Director
• Thomas Haughey,
  Independent Director
• Thomas Penn,
  Independent Director
• Patrick Walsh,
  Chairman of the Board
• David Nash,
  Independent Director
• Jeanne Thoma,
  Independent Director
• Antonio Pera,
  Independent Director
• Nikhil Lalwani,
  President, Chief Executive Officer, Director
• Muthasamy Shanmugam MS R.Ph.,
  Head of R&D and COO of Novitium Operations
• Ori Gutwerg,
  Sr. VP of Generics
• Christopher K. Mutz,
  Head of Rare Diseases
• Chad Gassert,
  Sr. VP of Corp. Devel. & Strategy
• Daniel Raynor,
  Director
• Arthur Przybyl,
  President and CEO
• Tracy Marshbanks,
  Director
• Fred Holubow,
  Director
• Peter A Lankau,
  Director
• Charlotte C. Arnold,
  Chief Financial Officer
• Renee P Tannenbaum,
  Director
• Ross J Mangano,
  Director
• Robert J. Jamnick,
  VP, Quality & Product Develop.
• Venture Partners Ii Lp Meri...,
  
• Ori Gutwerg,
  SVP, GENERICS
• Christopher Mutz,
  HEAD OF RARE DISEASE
• Krista Davis,
  SVP, CHIEF HR OFFICER
• Chad Gassert,
  SVP - CORP. DEV. & STRATEGY
• Meredith Cook,
  SR. VP, GENERAL COUNSEL & SEC.
• Muthusamy Shanmugam,
  HEAD OF R&D, COO-NOVITIUM OPS
• Matthew J Leonard,
  Director